The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Clinical trial NCT06930118 · RECRUITING
Trial details
- NCT number
- NCT06930118
- Sponsor
- Shanghai Changzheng Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-10
- Primary completion
- 2027-04-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.